Vinci Pharmaceuticals Raises Over $8 Million in Series A Financing

Vinci Pharmaceuticals has secured over $8 million in a Series A financing round. The company announced that the funding will support the manufacturing, testing, and release activities, as well as first-in-human studies for its EPIPLANT™ drug delivery platform.

Combined with its previous seed funding of $8.5 million, the company has now raised more than $16.5 million. These funds are intended to accelerate the drug development process and expand the company's research and development initiatives.

The EPIPLANT™ platform is being developed by Vinci Pharmaceuticals with the aim of improving drug delivery and efficacy. However, specific details regarding the platform's technological aspects or its targeted therapeutic areas have been limited.

The company has not disclosed the specific investors participating in this financing round. The capital raised is expected to propel the platform's development towards commercialization and clinical application.